Erlotinib, an inhibitor of the epidermal growth factor receptor widely used to treat unresectable non-small cell lung cancer, can improve the overall survival of patients with advanced pancreatic cancer by 0.33 months, but at the expense of greater adverse effects [19]. This evidence concerns the gene EGFR and pancreatic neoplasm.